Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2
Diabetes and Vascular Disease Research · 2021-01 · 18 (1)
DOI: 10.1177/1479164121995928 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diabetes and Vascular Disease Research, online erschienen am 20.02.2021. Verfasst von Helena W Rodbard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine and Metabolic Consultants, Rockville, MD, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
Evaluate the effect of sotagliflozin, a dual inhibitor of sodium glucose cotransporter (SGLT) 1 and 2, on arterial stiffness in patients with type 1 diabetes (T1D) treated with sotagliflozin as adjunct to optimized insulin therapy.
Methods
In this post hoc analysis, indirect markers of arterial stiffness, including pulse pressure, mean arterial pressure (MAP), and double product, were calculated using observed systolic blood pressure (SBP), diastolic blood pressure (DBP), or pulse rate at 24 weeks using data from a pooled patient population from the inTandem1 and inTandem2 randomized controlled trials ( n = 1575).
Results
Baseline characteristics were similar among groups. Relative to placebo at Week 24, sotagliflozin 200 mg and 400 mg reduced SBP by 2.03 mm Hg (95% CI −3.30 to −0.75; p = 0.0019) and 2.85 mm Hg (−4.12 to −1.57; p < 0.0001), respectively. DBP decreased by 1.1 and 0.9 mm Hg, MAP by 1.4 and 1.6 mm Hg, and double product by 202.5 and 221.1 bpm × mm Hg, respectively ( p < 0.05 for all). No increases in heart rate were observed.
Conclusion
In adults with T1D, adding sotagliflozin to insulin significantly reduced blood pressure and other markers of arterial stiffness and vascular resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrine and Metabolic Consultants, Rockville, MD, USA.
- Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy.
- L'institut du thorax, UNIV Nantes, CNRS Inserm, CHU Nantes, Nantes, France.
- Departments of Medicine and Pediatrics, Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO, USA.
- Lexicon Pharmaceuticals, Inc., The Woodlands, TX, USA.
- Esperion Therapeutics, Ann Arbor, MI, USA.
ORCID-Profile: Helena W Rodbard
Zitieren
APA
Rodbard, H. W., Giaccari, A., Cariou, B., Garg, S., Davies, M. J., Seth, K., & Sawhney, S. (2021). Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2. Diabetes and Vascular Disease Research, 18(1). https://doi.org/10.1177/1479164121995928
Vancouver
Rodbard HW, Giaccari A, Cariou B, Garg S, Davies MJ, Seth K, et al. Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2. Diabetes and Vascular Disease Research. 2021;18(1). doi:10.1177/1479164121995928
BibTeX
@article{Rodbard2021,
author = {Rodbard, Helena W and Giaccari, Andrea and Cariou, Bertrand and Garg, Satish and Davies, Michael J and Seth, Kiernan and Sawhney, Sangeeta},
title = {Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2},
journal = {Diabetes and Vascular Disease Research},
year = {2021},
volume = {18},
number = {1},
doi = {10.1177/1479164121995928}
}
EUVIMED